APOA5 and fatty liver disease: Moreover, recent study by Li and the colleagues demonstrated that olanzapine, a drug used for treating schizophrenia, increased intracellular ApoA5 levels by enhancing the interaction of ApoA5 and sortilin to impair its transport, then leading to hepatic steatosis 29; however, olanzapine treatment significantly increased plasma TG and TC concentration, accompanied with elevated AST and ALT levels.